NASDAQ:ALBO

Albireo Pharma Stock Forecast, Price & News

$35.06

+0.18 (+0.52 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$33.75

Now: $35.06▼

$35.15

50-Day Range

$34.88

MA: $38.43▼

$42.16

52-Week Range

$11.26

Now: $35.06▼

$49.00

Volume101,000 shs

Average Volume172,700 shs

Market Capitalization$668.84 million

P/E RatioN/A

Dividend YieldN/A

Beta1.62

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.53 out of 5 stars

Medical Sector

385th out of 1,923 stocks

Pharmaceutical Preparations Industry

200th out of 773 stocks

3.5 Analyst's Opinion

Consensus Rating
Albireo Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $69.43, Albireo Pharma has a forecasted upside of 98.0% from its current price of $35.06.
Amount of Analyst Coverage
Albireo Pharma has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Albireo Pharma has received 281 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Albireo Pharma has received 292 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Albireo Pharma has received 50.96% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote “Outperform” if you believe ALBO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Albireo Pharma does not currently pay a dividend.
Dividend Growth
Albireo Pharma does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Albireo Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,078.00 in company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Albireo Pharma is held by insiders.
Percentage Held by Institutions
85.65% of the stock of Albireo Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Albireo Pharma are expected to decrease in the coming year, from ($7.55) to ($8.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Albireo Pharma is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Albireo Pharma is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Albireo Pharma has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ALBO

Previous Symbol

CUSIPN/A

CIK1322505

Webwww.albireopharma.com

Phone(857) 254-5555

Employees55

Debt

Debt-to-Equity Ratio0.04

Current Ratio13.52

Quick Ratio13.51

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$9.64 million

Price / Sales69.38

Cash FlowN/A

Price / Cash FlowN/A

Book Value$7.34 per share

Price / Book4.78

Profitability

EPS (Most Recent Fiscal Year)($5.04)

Net Income$-62,720,000.00

Net Margins-751.53%

Return on Equity-71.22%

Return on Assets-42.91%

Miscellaneous

Outstanding Shares19,077,000

Market Cap$668.84 million

Next Earnings Date3/1/2021 (Estimated)

OptionableOptionable

$35.06

+0.18 (+0.52 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

How has Albireo Pharma's stock been impacted by Coronavirus?

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALBO stock has increased by 98.9% and is now trading at $35.06.
View which stocks have been most impacted by COVID-19.

Is Albireo Pharma a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Albireo Pharma?

Wall Street analysts have given Albireo Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Albireo Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Albireo Pharma.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) released its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($1.96) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.51) by $0.45. The biopharmaceutical company earned $2.13 million during the quarter, compared to analyst estimates of $1.90 million. Albireo Pharma had a negative trailing twelve-month return on equity of 71.22% and a negative net margin of 751.53%.
View Albireo Pharma's earnings history.

What price target have analysts set for ALBO?

8 Wall Street analysts have issued 1-year price targets for Albireo Pharma's stock. Their forecasts range from $52.00 to $81.00. On average, they anticipate Albireo Pharma's stock price to reach $69.43 in the next year. This suggests a possible upside of 98.0% from the stock's current price.
View analysts' price targets for Albireo Pharma or view Wall Street analyst' top-rated stocks.

Who are some of Albireo Pharma's key competitors?

Some companies that are related to Albireo Pharma include Intra-Cellular Therapies (ITCI), Deciphera Pharmaceuticals (DCPH), Amarin (AMRN), Arcus Biosciences (RCUS), Zymeworks (ZYME), ADC Therapeutics (ADCT), Ligand Pharmaceuticals (LGND), Stoke Therapeutics (STOK), Seres Therapeutics (MCRB), Praxis Precision Medicines (PRAX), Shattuck Labs (STTK), Harmony Biosciences (HRMY), PMV Pharmaceuticals (PMVP), NGM Biopharmaceuticals (NGM) and Kura Oncology (KURA).
View all of ALBO's competitors.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:

Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 58, Pay $838.51k)
Dr. Patrick T. Horn, Chief Medical Officer (Age 66, Pay $588.46k)
Ms. Pamela Stephenson M.P.H., Chief Commercial Officer (Age 53, Pay $469.19k)
Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
Dr. Jan P. Mattsson, Chief Scientific Officer & MD (Sweden) and Co-Founder (Age 57)
Mr. Simon N.R. Harford, CFO & Treasurer (Age 60)
Mr. Jason G. Duncan, Chief Legal Officer, Gen. Counsel & Sec. (Age 46)
Ms. Michelle Graham, Chief HR Officer (Age 54)
Dr. Kristina TorfgÃ¥rd, VP & Global Project Head
Ms. Martha J. Carter, Chief Regulatory Officer (Age 69)

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Pacer Advisors Inc. (0.01%). Company insiders that own Albireo Pharma stock include Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc and Simon NR Harford.
View institutional ownership trends for Albireo Pharma.

Which institutional investors are buying Albireo Pharma stock?

ALBO stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Albireo Pharma or or view top insider-buying stocks.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $35.06.

How big of a company is Albireo Pharma?

Albireo Pharma has a market capitalization of $668.84 million and generates $9.64 million in revenue each year. The biopharmaceutical company earns $-62,720,000.00 in net income (profit) each year or ($5.04) on an earnings per share basis. Albireo Pharma employs 55 workers across the globe.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is www.albireopharma.com.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at (857) 254-5555 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here